BioAge Labs (BIOA) Cash from Financing Activities (2023 - 2026)

BioAge Labs has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $16.0 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 1164.4% year-over-year to $16.0 million; the TTM figure through Jun 2026 stood at $154.2 million (down 27.49% YoY), while the FY2025 annual figure was $11.5 million, down 96.99% from the prior year.
• Cash from Financing Activities came in at $16.0 million for Q2 2026 at BioAge Labs, down from $123.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q3 2024 to a low of -$2.4 million in Q2 2024.
• Average Cash from Financing Activities over 4 years is $48.3 million, with a median of $16.0 million recorded in 2026.
• Year-over-year, Cash from Financing Activities tumbled 100.89% in 2025 and jumped 8347.67% in 2026.
• Over 4 years, Cash from Financing Activities stood at -$1.0 million in 2023, then jumped by 2567.99% to $24.9 million in 2024, then slumped by 35.7% to $16.0 million in 2025, then slipped by 0.29% to $16.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $16.0 million in Q2 2026, $123.7 million in Q1 2026, and $16.0 million in Q4 2025.